Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
To compare efficacy and safety for deep anterior lamellar keratoplasty (DALK) versus penetrating keratoplasty (PK) for macular corneal dystrophy. Following PRISMA guidelines, we searched four electronic databases (PubMed, Scopus, Cochrane Library, and Web of Science) to identify eligible studies reported up to January 2024. Using STATA 17, we reported outcomes as log risk ratios (log RRs) or mean difference (SMD) and confidence intervals (CIs). A value ≤ 0.05 is considered statistically significant. DALK was superior to PK in terms of BCVA (Hedge's g: -0.32 with 95% CI [-0.64, -0.01], =0.05), PK was associated with a higher risk of graft rejection in comparison with DALK (log RR: 1.21 with 95% CI [0.25, 2.18], =0.01), and there was no difference between PK and DALK in terms of risk of glaucoma, cataract (log RR: -0.02 with 95% CI [-1.00, 0.95], =0.96), and (log RR: 0.09 with 95% CI [-0.53, 0.71], =0.78). The pooled data were homogeneous ( = 0%; =0.84), respectively. This study suggests that PK, compared to DALK, is associated with worse visual outcomes, with a lower risk of recurrence and a higher risk of graft rejection in macular corneal dystrophy patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349984 | PMC |
| http://dx.doi.org/10.1155/joph/8867750 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Antiviral Strategies to Combat African Swine Fever.
FEMS Microbiol Rev
September 2025
CIISA - Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal.
African Swine Fever (ASF), caused by the highly contagious African swine fever virus (ASFV), poses a significant threat to domestic and wild pigs worldwide. Despite its limited host range and lack of zoonotic potential, ASF has severe socio-economic and environmental consequences. Current control strategies primarily rely on early detection and culling of infected animals, but these measures are insufficient given the rapid spread of the disease.
View Article and Find Full Text PDFElinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).
The Safety Profile of Belzutifan in Renal Tumors: Real-World Data from a Tertiary Academic Center.
Oncologist
September 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Background: Belzutifan is a HIF-2ɑ inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials, however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.
View Article and Find Full Text PDFTargeting CD20 for B-cell Depletion in Autoimmune Kidney Disease: Next Generation.
BioDrugs
September 2025
Department of Nephrology, Instituto de Investigación Hospital "12 de Octubre" (imas12), Avda. De Córdoba s/n, 28041, Madrid, Spain.
Anti-CD20 monoclonal antibodies are gaining clinical relevance in the nephrology community due to their demonstrated efficacy and favorable safety profiles across short-, medium-, and long-term use. Initially developed for hematologic malignancies and multiple sclerosis, B-cell depletion therapies are now being investigated across a broader spectrum of autoimmune diseases, including glomerulopathies, both with and without associated podocytopathy. Recent advances have led to the development of novel anti-CD20 agents that are being used not only as potential alternatives to corticosteroids but also as adjunctive therapies in complex clinical settings.
View Article and Find Full Text PDFDesign of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDF